» Articles » PMID: 33425706

Development and Validation of an Ultra-performance Liquid Chromatography Mass Spectrometry/mass Spectrometry Method for Simultaneous Quantification of Total and Free Mycophenolic Acid and Its Metabolites in Human Plasma

Overview
Date 2021 Jan 11
PMID 33425706
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

A reliable method has been validated using ultra-performance liquid chromatography mass spectrometry (MS)/MS for simultaneous evaluation of human plasma concentration of mycophenolic acid (MPA) and its major metabolites both total and free form. All analytes were extracted from plasma by simple protein precipitation procedure with methanol. Samples for determination of their free form concentration require a preanalytic spin through an ultrafiltration system. The chromatographic separation was completed using Ccolumn at 0.3 ml/min with a gradient condition. Method validation was performed as the United State Food and Drug Administration guidelines for bio-analytical methods concerning precision, accuracy, linearity, selectivity, recovery, and matrix effect. Linearity was obtained over concentration of 0.05-4, 0.5-60, and 0.025-3 μg/ml for total MPA, mycophenolic acid glucuronide (MPAG) and mycophenolic acid acyl-glucuronide (AcMPAG), respectively. The linearity of the method for free form of analytes was confirmed in the range of 10-500, 125-10,000, and 0.5-300 ng/ml for MPA, MPAG, and AcMPAG, respectively. The intra- and interday accuracy ranged from 85.73%-102.01% for total form, and 87.23%-111.89% for free form, and the precisions of all analytes were lower than 15%. The mean recoveries of the analytes ranged from 85.54% to 94.76% and the matrix factor ranged from 0.88-1.06. The developed method is rapid, sensitive and convenient for pharmacokinetic study or therapeutic drug monitoring in patients after oral administration of enteric-coated mycophenolate sodium or mycophenolate mofetil.

Citing Articles

Development and validation of an automated solid-phase extraction-LC-MS/MS method for the bioanalysis of fluoxetine in human plasma.

Ahmad I, Ullah Z, Khan M, Alahmari A, Khan M J Adv Pharm Technol Res. 2021; 12(3):267-273.

PMID: 34345606 PMC: 8300324. DOI: 10.4103/japtr.JAPTR_308_20.

References
1.
Garg U, Munar A, Frazee C . Determination of Mycophenolic Acid and Mycophenolic Acid Glucuronide Using Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS). Curr Protoc Toxicol. 2018; 75:18.21.1-18.21.8. DOI: 10.1002/cptx.42. View

2.
Bullingham R, Nicholls A, Kamm B . Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998; 34(6):429-55. DOI: 10.2165/00003088-199834060-00002. View

3.
Gao X, Tsai R, Ma J, Bhupal P, Liu X, Liang D . Determination and validation of mycophenolic acid by a UPLC-MS/MS method: Applications to pharmacokinetics and tongue tissue distribution studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2019; 1136:121930. DOI: 10.1016/j.jchromb.2019.121930. View

4.
Shipkova M, Schutz E, Armstrong V, Niedmann P, Oellerich M, Wieland E . Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem. 2000; 46(3):365-72. View

5.
Budde K, Glander P, Diekmann F, Waiser J, Fritsche L, Dragun D . Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother. 2004; 5(6):1333-45. DOI: 10.1517/14656566.5.6.1333. View